Busca un médico

Mashal J. Batheja, M.D.

  1. Gastroenterologist

Publicaciones

  1. Batheja MA. Continuing Medical Education Questions: February 2024. Am J Gastroenterol. 2024 Feb 1; 119 (2):247
    View PubMed
  2. Tran NH, Almodallal Y, Batheja M, Martin NA, Le-Rademacher J, Ridgeway JL, Sia IG, Jatoi A. Social determinants of health: a need for better data capture in Asian American patients with hepatocellular cancer. Support Care Cancer. 2023 Aug 30; 31 (9):543
    View PubMed
  3. Arca KN, Cai J, Wang F, Kassim G, Hasler WL, Batheja MJ. Migraine and Gastroparesis. Curr Neurol Neurosci Rep. 2022 Dec; 22(12):813-821. Epub 2022 Nov 12.
    View PubMed
  4. Batheja M, Vargas H, Silva AM, Walker F, Chang YH, De Petris G, Silva AC. Magnetic resonance elastography (MRE) in assessing hepatic fibrosis: performance in a cohort of patients with histological data. Abdom Imaging. 2015 Apr; 40: (4)760-5.
    View PubMed
  5. Gallegos-Orozco JF, Silva AC, Batheja MJ, Chang YH, Hansen KL, Lam-Himlin D, De Petris G, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan DC, Silva AM, Rakela J, Vargas HE. Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Abdom Imaging. 2014 Dec 02.
    View PubMed
  6. Batheja M, Harrison ME, Das A, Engel R, Crowell M. Optimal positioning for ERCP: efficacy and safety of ERCP in prone versus left lateral decubitus position. ISRN Endoscopy, Article ID 810269. 2013; 2013.
  7. Batheja MJ, Leighton J, Azueta A, Heigh R. The Face of Tropical Sprue in 2010. Case Rep Gastroenterol. 2010 May 19; 4 (2):168-172
    View PubMed
  8. Decker GA, Batheja MJ, Collins JM, Silva AC, Mekeel KL, Moss AA, Nguyen CC, Lake DF, Miller LJ. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y). 2010 Apr; 6(4):246-54.
    View PubMed
  9. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl. 2009 Aug; 15 (8):859-68
    View PubMed
  10. Silva AC, Evans JM, McCullough AE, Jatoi MA, Vargas HE, Hara AK. MR imaging of hypervascular liver masses: a review of current techniques. Radiographics. 2009 Mar-Apr; 29 (2):385-402
    View PubMed
  11. Nabhan C, Rundhaugen LM, Riley MB, Rademaker A, Boehlke L, Jatoi M, Tallman MS. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res. 2005 Jan; 29(1):53-7.
    View PubMed
  12. Nabhan C, Rundhaugen L, Jatoi M, Riley MB, Boehlke L, Peterson LC, Tallman MS. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol. 2004 Aug; 15(8):1231-6.
    View PubMed
PST-20520269